Quest Award, Funded by the Griffin Leadbetter Award

Targeting The Chloride Transporter NKCC1 For Seizure Suppression In Tuberous Sclerosis Complex (TSC)

Delia Talos, MD
Children’s Hospital, Boston/ Harvard Medical School

Epilepsy is a common and devastating occurrence for individuals with Tuberous Sclerosis Complex (TSC), and conventional antiepileptic drugs are often of limited benefit. Nerve cells affected by this genetic disease cannot react appropriately to certain inhibitory signals mediated by chemical neurotransmitters. Dr. Talos’ research will examine the altered nerve cell response in TSC, and determine if this alteration plays a crucial role in seizure development and the brain’s ability to respond to medication. Her study will investigate alterations of brain cell response to inhibitory signals in individuals with TSC, with the goal of identifying new therapeutic targets and developing more effective approaches to treat epilepsy.


    Join our email list for the
    latest epilepsy research news,
    discoveries, and more.